Affordable Access

deepdyve-link
Publisher Website

Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.

Authors
  • Goodman-Meza, David1
  • Beymer, Matthew R1, 2
  • Kofron, Ryan M3
  • Amico, K Rivet4
  • Psaros, Christina5
  • Bushman, Lane R6
  • Anderson, Peter L6
  • Bolan, Robert2
  • Jordan, Wilbert C7
  • Rooney, James F8
  • Wohl, Amy R9
  • Landovitz, Raphael J1, 3
  • 1 a Division of Infectious Diseases, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
  • 2 b Health and Mental Health Services, Los Angeles LGBT Center , Los Angeles , CA , USA.
  • 3 c UCLA Center for Clinical AIDS Research & Education (CARE) , Los Angeles , CA , USA.
  • 4 d Department of Health Behavior and Health Education, University of Michigan School of Public Health , Ann Arbor , MI , USA.
  • 5 e Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital , Boston , MA , USA.
  • 6 f Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado , Aurora , CO , USA.
  • 7 g OASIS Clinic, Charles R. Drew University of Medicine and Science , Los Angeles , CA , USA.
  • 8 h Gilead Sciences , Foster City , CA , USA.
  • 9 i Division of HIV and STD Programs, Los Angeles County Department of Public Health , Los Angeles , CA , USA.
Type
Published Article
Journal
AIDS care
Publication Date
Oct 01, 2019
Volume
31
Issue
10
Pages
1228–1233
Identifiers
DOI: 10.1080/09540121.2019.1595523
PMID: 30894013
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

PrEP's potential benefit for men who have sex with men (MSM) who use stimulants may be limited by adherence or prescriber willingness to recommend PrEP due to concerns of non-compliance. Using data from PATH-PrEP, a 48-week study evaluating PrEP for MSM in Los Angeles, we modeled an interaction between stimulant use and condomless sex with multiple partners (CAS-MP) on prevention-effective dried blood spot tenofovir-diphosphate concentrations. At week 4, participants reporting stimulant use and CAS-MP had a decreased odds of prevention-effective adherence compared to non-stimulant use and non-CAS-MP (AOR 0.15, 95% CI 0.04-0.57). From week 4-48, participants reporting stimulant use and CAS-MP had increased odds of prevention-effective adherence (AOR 1.06 per week, 95%CI 1.01-1.12). Participants reporting CAS-MP without stimulant use had no significant change in prevention-effective adherence (AOR 0.99 per week, 95%CI 0.96-1.02). Stimulant use moderated the association of CAS-MP on prevention-effective PrEP adherence over time.

Report this publication

Statistics

Seen <100 times